France Cancer Immunotherapy Market Insight
Published: 04 June 2026 | Report Format: Electronic (PDF)
The France Cancer Immunotherapy Market will grow at a rate of 4.89% due to National Cancer Strategy, Rising Disease Prevalence, Technological & Therapeutic Advancements, Shift to Personalized Medicine.
France Cancer Immunotherapy Market Insights Forecasts to 2035
- The France Cancer Immunotherapy Market Size Was Estimated USD 3.75 Billion n in 2025
- The Market Size is Expected to Grow at a CAGR of around 4.89% from 2025 to 2035
- The France Cancer Immunotherapy Market Size is Expected to rise around USD 6.05 Billion by 2035
Notable Insights for the France Cancer Immunotherapy Market
- Segmentation on the basis of Product Type indicates that With a market share of about 33%, the monoclonal antibodies sector dominates the French cancer immunotherapy market in 2025 because of its focused efficacy, wide range of therapeutic uses, and rising hospital adoption.
- Segmentation on the basis of End Users indicates that with a nearly 65% market share in 2025, the hospitals and clinics category dominates the French cancer immunotherapy market thanks to its sophisticated treatment infrastructure, specialised oncology services, and large patient volume.
- Launched by the Institut Curie's Paris-Saclay Cancer Cluster, CellAction maintains 600 m² facilities with €13.7 million in financing to promote CAR-T and cell therapy research through public-private partnerships.
- By giving Egle Therapeutics and ImCheck Therapeutics €29.48 million in non-dilutive funding for clinical-stage immuno-oncology development, France 2030 and Bpifrance expedited the development of cancer immunotherapy.
Download the eBook (ToC)
Why Buy This Report
- Unlock critical market intelligence: Detailed insights into the size, growth predictions (2025-2035), prevalent trends, opportunities, and competitive landscape in France's cancer immunotherapy market.
- Pinpoint high-growth niches and investment prospects: In-depth segmentation of the market by therapy types, cancer type, end-users and evolving technologies like CAR-T, and checkpoint inhibitors.
- Augment decision-making with actionable data: Understand the impacts of regulatory changes, reimbursement structures, progress of the clinical pipeline, government grants, and profile of market participants.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Cancer Immunotherapy Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Cancer Immunotherapy Market
- Sanofi
- Innate Pharma
- OSE Immunotherapeutics
- Cellectis
- Transgene
- ImCheck Therapeutics
- Bristol Myers Squibb
- Merck (MSD)
- Roche
- Novartis
Recent Developments:
- In April 2025, Sanofi strengthened its immuno-oncology partnership with Innate Pharma through a €15 million strategic investment, supporting development of ANKET NK-cell engager therapies and expanding next-generation immunotherapy programs.
- In March 2025, Egle Therapeutics secured €9.3 million under the France 2030 biotherapies program to accelerate clinical development of EGL-001, its Treg-targeting immuno-oncology candidate currently advancing through Phase I/II studies.
Market Segmentation:
France Cancer Immunotherapy Market, By Therapy Type
- Monoclonal Antibodies
- Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4 inhibitors)
- Cancer Vaccines
- Therapeutic T-Cell Therapies (including CAR-T)
- Oncolytic Virus Therapy
- Immunomodulators and Cytokine Therapies
France Cancer Immunotherapy Market, By End Users
- Hospitals
- Oncology Clinics
- Cancer Research Institutes/Centers
- Diagnostic Laboratories
- Other Healthcare Facilities
France Cancer Immunotherapy Market, By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Head & Neck Cancer
- Ovarian Cancer
- Pancreatic Cancer
Expert Views:
France's cancer immunotherapy market is all set to maintain a stable growth trajectory through 2035 on account of robust government initiatives, escalating use of precision oncology and relentless advancement in monocloncal antibodies and cell therapies. Government funded schemes, established clinical research infrastructure and rising incidences of cancer would reinforce growth for the market, while the top-notch domestic and international companies make France a central point for immunotherapy in Europe.
Author: Govind and Krishna By Spherical Insights and Consulting